Daily Endocrinology Research Analysis
Analyzed 76 papers and selected 3 impactful papers.
Summary
Analyzed 76 papers and selected 3 impactful articles.
Selected Articles
1. Ets1-dependent Mek-Erk signaling drives adipose tissue macrophage anti-inflammatory polarization to ameliorates insulin resistance.
The study identifies Ets1 as an IL-4–specific downstream effector that links Mek–Erk signaling to anti-inflammatory macrophage polarization via IRF4 upregulation and chromatin remodeling. Myeloid Ets1 deficiency worsened adipose inflammation and metabolic dysfunction, suggesting a mechanistic node separating pro- vs. anti-inflammatory Erk outputs.
Impact: This mechanistic work uncovers a discriminator (Ets1) that resolves how Erk signaling yields divergent immune outputs, advancing immunometabolism and offering a tractable target to modulate metabolic inflammation.
Clinical Implications: Targeting the Ets1–IRF4 axis could enhance anti-inflammatory polarization in adipose tissue macrophages to ameliorate insulin resistance; caution is warranted when using Mek–Erk inhibitors given context-specific effects.
Key Findings
- Ets1 transcriptional activity is selectively activated by IL-4 via Thr38 phosphorylation despite broad Erk activation by diverse stimuli.
- Myeloid-specific Ets1 knockout mice develop exacerbated adipose inflammation and metabolic dysfunction in lean and obese states.
- Ets1 upregulates Irf4 and remodels chromatin to drive anti-inflammatory macrophage polarization, functionally coupling Mek–Erk to IL-4 responses.
Methodological Strengths
- Mechanistic dissection with myeloid-specific knockout mice linking molecular signaling to in vivo metabolic phenotypes
- Convergent evidence including phosphorylation-dependent activation, transcriptional control, and chromatin remodeling
Limitations
- Preclinical study with no human interventional validation
- Scope limited to selected stimuli; generalizability across tissue macrophage niches requires testing
Future Directions: Test pharmacologic modulation of the Ets1–IRF4 pathway in metabolic disease models and assess translational relevance in human adipose tissue macrophages.
Clinical observations reveal that Mek-Erk inhibitors exert paradoxical immunoregulatory effects on macrophages, yet the mechanisms governing the pathway's specific immunoregulatory outputs remain elusive. Here, we identify Ets1 as a discriminative effector that couples Mek-Erk signaling specifically to anti-inflammatory polarization. We show that while various stimuli activate Erk, only the anti-inflammatory IL-4 activates the transcriptional activity of Ets1 in a Thr38 (T38) phosphorylation-dependent manner. Functionally, myeloid-specific Ets1 knockout mice exhibited exacerbated adipose inflammation and metabolic dysfunction under both physiological and obesity conditions. Mechanistically, Ets1 raises Irf4 expression level via both transcriptional regulation and chromatin remodeling, thereby inducing macrophage anti-inflammatory polarization. Taken together, we demonstrate that Ets1 serves as a critical discriminator activated specifically by IL-4 stimulation but remaining inactive under pro-inflammatory conditions. This bifurcated activation enables Erk signaling to differentially engage downstream effectors based on upstream stimuli, thereby directing macrophage functional specialization.
2. Early Initiation of Automated Insulin Delivery at Type 1 Diabetes Diagnosis in Children and Adolescents Is Associated with Improved Outcomes.
Among 9,856 youth across 27 centers, initiating automated insulin delivery within 6 months of diagnosis was associated with substantially lower HbA1c at 24 months compared with no AID use and with lower risk of DKA. Findings support prioritizing timely and equitable access to AID soon after type 1 diabetes diagnosis.
Impact: Provides large-scale, real-world evidence that earlier AID adoption confers durable glycemic benefits and fewer acute complications, informing care pathways and coverage policies.
Clinical Implications: Encourage AID initiation within the first 6 months after diagnosis when feasible, address access barriers, and integrate AID education early to optimize long-term glycemic outcomes and reduce DKA.
Key Findings
- Earlier AID initiation (<6 months) was associated with a markedly lower 24-month HbA1c (median 7.1%) compared with non-users (9.8%).
- Early AID use correlated with reduced incidence of diabetes-associated ketoacidosis over 24 months.
- Timing of AID initiation stratified long-term glycemic trajectories in a large, multicenter cohort.
Methodological Strengths
- Large multicenter cohort (27 U.S. centers) with 24-month follow-up
- Clear stratification by timing of device initiation enabling dose–response inference
Limitations
- Retrospective observational design susceptible to selection bias and unmeasured confounding
- Details on time-in-range and device-specific algorithms were not reported in the abstract
Future Directions: Prospective or randomized studies to test early AID initiation strategies, assess equity-focused implementation, and evaluate glycemic metrics (time-in-range) and quality of life.
INTRODUCTION: This retrospective cohort study evaluates the impact of timing of automated insulin delivery (AID) initiation on glycemic outcomes in youth with type 1 diabetes. METHODS: Data from 9856 children and adolescents diagnosed with type 1 diabetes between 2020 and 2022 across 27 U.S. centers were analyzed. Participants were grouped by AID initiation timing in months: <6, 6-12, 13-24, or no AID use. Hemoglobin A1c (HbA1c) trajectories, diabetes-associated ketoacidosis (DKA), and severe hypoglycemia rates were assessed over 24 months after T1D diagnosis. RESULTS: Earlier AID initiation was associated with lower HbA1c at 24 months (median 7.1% in the <6-month group vs. 9.8% in non-users, CONCLUSIONS: Early AID initiation is associated with improved glycemic control and reduced DKA risk, underscoring the importance of timely and equitable access to AID systems.
3. SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.
Across >430,000 patients with AKI, post-AKI exposure to SGLT2 inhibitors or GLP-1 receptor agonists was associated with lower odds of major adverse kidney events and mortality; SGLT2i also reduced the need for kidney replacement therapy in available studies. Predominantly observational evidence calls for randomized trials.
Impact: Addresses a key evidence gap on cardio-renal-metabolic therapy timing after AKI and suggests potential survival and kidney benefits, informing post-AKI management strategies.
Clinical Implications: Consider early reassessment for initiation or re-initiation of SGLT2i/GLP-1RA after stabilization from AKI, with careful patient selection and monitoring; await RCT data for definitive guidance.
Key Findings
- Post-AKI exposure to SGLT2i/GLP-1RA was associated with lower MAKE (OR 0.63, 95% CI 0.46–0.86) and all-cause mortality (OR 0.36, 95% CI 0.21–0.62).
- SGLT2i reduced odds of kidney replacement therapy where assessed (OR 0.61, 95% CI 0.40–0.93).
- Sensitivity analyses restricted to SGLT2i data yielded consistent results, supporting robustness.
Methodological Strengths
- Comprehensive multi-database search with random-effects meta-analysis
- Very large aggregated sample (N=432,048) and consistent sensitivity analyses
Limitations
- Predominantly observational evidence with potential residual confounding and selection bias
- Heterogeneity in definitions, timing of exposure, and follow-up across studies
Future Directions: Conduct randomized controlled trials to evaluate timing and safety of initiating SGLT2i/GLP-1RA after AKI and to define subgroups with maximal benefit.
Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are nephroprotective and their use is recommended for adults with chronic kidney disease (CKD). The role of SGLT2i and GLP-1 RAs in patients with acute kidney injury (AKI) is unknown. This systematic review aimed to estimate the effect of SGLT2i or GLP-1 RAs on clinical outcomes in AKI. We systematically searched Embase, MEDLINE, Scopus, Web of Science Core Collection, and clinical trials registries for observational studies and clinical trials from database inception to July 3, 2025. Included studies evaluated adults (≥ 18 years) with AKI during a hospitalization and compared patients subsequently exposed to either SGLT2i or GLP-1 RAs to a non-exposed control group. Random effects meta-analyses were performed. Six studies related to SGLT2i (five observational, one randomized trial) and one related to GLP-1 RAs (one observational) met eligibility criteria (N = 432,048 patients). SGLT2i/GLP-1 RA exposure was associated with lower odds of major adverse kidney events (MAKE) (OR 0.63, 95% CI 0.46-0.86) and all-cause mortality [odds ratio (OR) 0.36, 95% confidence interval (CI) 0.21-0.62] compared to controls. The odds for kidney replacement therapy were lower with SGLT2i therapy in the three studies where it was evaluated (OR 0.61, 95% CI 0.40-0.93). Sensitivity analyses restricted to SGLT2i data were consistent with the overall findings [MAKE OR 0.63 (95% CI 0.42-0.95); Mortality OR 0.34 (95% CI 0.18, 0.65)]. Exposure to SGLT2i or GLP-1 RAs after AKI, examined primarily in observational studies, was associated with improved clinical outcomes. These findings are promising and warrant evaluation in randomized clinical trials.